ATAI Life Sciences shareholders approve acquisition of Beckley Psytech and redomiciliation

ATAI Life Sciences shareholders have approved the acquisition of Beckley Psytech, a move that represents a significant step in the company's growth strategy. This acquisition is expected to enhance ATAI's portfolio, expanding its capabilities and market presence. Alongside the acquisition, the company is also undergoing a redomiciliation, which is intended to better position ATAI for future success. The shareholders' approval indicates strong support for these strategic initiatives. Together, these actions reflect ATAI Life Sciences' commitment to strengthening its business foundation and pursuing long-term growth opportunities. The combination of acquiring Beckley Psytech and redomiciling suggests a coordinated effort to optimize the company's structure and operations. This development marks an important milestone in ATAI's ongoing expansion efforts.